Using baseline cognitive severity for enriching Alzheimer's disease clinical trials: How does Mini-Mental State Examination predict rate of change?
BACKGROUND
Post hoc analyses from clinical trials in Alzheimer's disease suggest more cognitively impaired participants respond differently from less impaired on cognitive outcomes. We examined pooled clinical trials data to assess the utility of enriching trials using baseline cognition.


METHODS
We included 2,882 participants with mild to moderate AD in 7 studies from a meta-database. We used mixed effects models to estimate rate of decline in ADAS-cog scores among MMSE groups.


RESULTS
Baseline MMSE category was associated with baseline scores and rate of decline on the ADAS-cog, adjusting for age and education (both p<0.001). Greater baseline cognitive impairment was associated with more rapid progression.


CONCLUSIONS
Although we found significant differences in rate of decline, the majority of differences between individuals were from baseline ADAS-cog values. Enrichment based on MMSE would reduce the recruitment pool while adding only slightly to detecting differences in rate of progression and is not advised.
University of Alabama, Birmingham, Birmingham, Alabama.
Richard E
RE
Kennedy
University of Alabama, Birmingham, Birmingham, Alabama.
Gary R
GR
Cutter
University of Alabama, Birmingham, Birmingham, Alabama.
Guoqiao
G
Wang
University of Southern California Keck School of Medicine, Los Angeles, California.
Lon S
LS
Schneider
Alzheimer disease; Alzheimer’s Disease Assessment Scale; Alzheimer’s Disease Cooperative Study (ADCS); Alzheimer’s Disease Neuroimaging Initiative (ADNI); Mini-Mental State Examination; clinical trials; clinical trials and methods; simulations
J Alzheimers Dis. 2013;37(1):173-83
23803296
Int J Geriatr Psychiatry. 2005 Jun;20(6):559-69
15920715
J Biopharm Stat. 2009;19(2):227-46
19212876
Neurology. 2011 Apr 19;76(16):1389-94
21502597
JAMA. 2008 Oct 15;300(15):1774-83
18854539
BMC Geriatr. 2013 Jun 06;13:56
23742728
JAMA. 2000 Feb 23;283(8):1007-15
10697060
N Engl J Med. 1997 Apr 24;336(17):1216-22
9110909
Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S13-21
9236948
Neurology. 2000 Feb 8;54(3):588-93
10680787
JAMA. 2010 Nov 3;304(17):1903-11
21045096
Alzheimers Dement. 2013 Jul;9(4):438-44
23809364
Arch Gen Psychiatry. 2011 Aug;68(8):853-61
21810649
J Psychiatr Res. 1975 Nov;12(3):189-98
1202204
JAMA. 2003 Jun 4;289(21):2819-26
12783912
Neurology. 2011 Aug 9;77(6):556-63
21795660
Alzheimers Dement. 2011 Mar;7(2):151-60
20810324
Neurology. 2010 Jan 19;74(3):201-9
20042704
Int Rev Psychiatry. 2008 Aug;20(4):389-95
18925488
Am J Geriatr Psychiatry. 2006 Feb;14(2):139-44
16473978
Alzheimers Dement. 2014 May;10 (3):349-59
23712001
Neurology. 1984 Jul;34(7):939-44
6610841
Alzheimers Dement. 2010 Sep;6(5):367-77
20813339